<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017233</url>
  </required_header>
  <id_info>
    <org_study_id>PD_CT_Hawk_2021_11258</org_study_id>
    <nct_id>NCT05017233</nct_id>
  </id_info>
  <brief_title>Spectral CT Clinical Trial Protocol</brief_title>
  <official_title>Spectral CT Clinical Trial Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips (China) Investment CO., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philips (China) Investment CO., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the expected effectiveness, ease of operation,&#xD;
      stability, and safety of Spectral CT&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Excellent and good rate of clinical imaging (score≥3）</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Rated items 5 points Excellent image quality for diagnostic purposes, very satisfactory 4 points good image quality, can be used for diagnosis, satisfactory 3 points Image quality defects, do not affect the diagnosis, general 2. Unsatisfactory image quality, affecting diagnosis Poor image quality, undiagnosable, unsatisfactory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Common functions assessment</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Common function evaluation items inclduing:The exposure function; Bed body moving; Microphone intercom function; Image post-processing function; Data storage management. With Satisfied, normal, Not Satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Convenience evaluation assessment</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Convenience function evaluation items inclduing:Laser positioning lamp Breathing navigation Control buttons The clinical interface friendliness of postprocessing software The post-processing software is convenient for clinical use and operation. With Satisfied, normal, Not Satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Machine function and stability assessment</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Machine function and stability evaluation items inclduing:workflow Image display and transmission Failed to start system Unexpected system shutdown Abnormal termination during the scan Unable to expose during scan. With Satisfied, normal, Not Satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Adverse events and serious adverse events during the test were collected to evaluate the safety of the product.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">86</enrollment>
  <condition>CT Scanning</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectral CT</intervention_name>
    <description>Using Spectral CT to scan Breast</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        volunteers (ages 18 to 75)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recruit volunteers (ages 18 to 75);&#xD;
&#xD;
          -  Negative pregnancy tests in women of childbearing age;&#xD;
&#xD;
          -  Participants who agree to participate in this clinical trial and sign the informed&#xD;
             consent;&#xD;
&#xD;
          -  Enhanced scans require laboratory tests to confirm normal renal function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons who do not have full capacity for civil conduct;&#xD;
&#xD;
          -  Lactating women;&#xD;
&#xD;
          -  People who are not suitable for enhanced scanning with iodine contrast agent;&#xD;
&#xD;
          -  Patients whom the investigator considers inappropriate to participate in this clinical&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan Shi Liu, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hua Fu Yan, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bin Song, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bin Wu</last_name>
    <phone>17721150107</phone>
    <email>bin.wu_1@philips.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

